The effects of magnesium on vascular stiffness: a long-term study in healthy overweight and slightly obese men and women. - Magnesium and Vascular Stiffness

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 58 人开始时间: 待定最近更新: 2024年4月23日

试验速览

暂无简介。

•- Aged between 45-70 years
•- Women postmenopausal: two or more years after last menstruation
•- BMI between 25-35 kg/m2 (overweight and slightly obese)
•- Plasma glucose < 7.0 mmol/L
•- Serum total cholesterol < 8.0 mmol/L
•- Serum triacylglycerol < 4.5 mmol/L
•- No current smoker
•- No diabetic patients
•- No familial hypercholesterolemia
•- No abuse of drugs
•- Less than 14 (women) or 21 (men) alcoholic consumptions per week
•- Stable body weight (weight gain or loss <3 kg in the past three months)
•- No use of proton pump inhibitors or medication known to treat blood pressure, serum lipid or glucose metabolism
•- No use of dietary supplements or an investigational product within another biomedical within the previous 1-month
•- No severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
•- No active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebro vascular accident
•- Willingness to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study
•- No difficult venipuncture as evidenced during the screening visit

•- High habitual dietary magnesium intake
•- Plasma glucose * 7.0 mmol/L
•- Serum total cholesterol * 8.0 mmol/L
•- Serum triacylglycerol * 4.5 mmol/L
•- Current smoker, or smoking cessation <12 months
•- Diabetic patients
•- Familial hypercholesterolemia
•- Abuse of drugs
•- More than 14 (women) or 21 (men) alcoholic consumptions per week
•- Unstable body weight (weight gain or loss > 3 kg in the past three months)
•- Use of proton pump inhibitors or medication known to treat blood pressure, serum lipid or glucose metabolism
•- Use of dietary supplements or an investigational product within another biomedical within the previous 1-month
•- Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
•- Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebro vascular accident
•- Not willing to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study
•- Not or difficult to venipuncture as evidenced during the screening visit

发起方

Medisch Universitair Ziekenhuis Maastricht